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ABSTRACT
Objective: To investigate the medical management costs
of estrogen plus progestogen hormone therapy (HT)
among postmenopausal women taking HT primarily as a
preventive treatment for osteoporosis.
Design: Retrospective longitudinal comparative analysis
of HT users and demographically matched nonusers using
administrative databases on physician services, hospital
stays and prescription medications. Setting: Saskatch-
ewan, Canada. Patients: a total of 5762 women aged
55 years or more who took HT sometime between 1990
and 1997 and 5762 demographically matched controls
who did not take HT from 1990 to 1997. Main outcome
measures: total medical care expenditures and apparent
costs of managing adverse events associated with HT.
Results: Excluding drug acquisition costs for HT and
costs of care for osteoporosis, women in their ﬁrst year of
postmenopausal HT had total medical care costs about
$400 greater than women who had never used HT (1997
Canadian dollars). This total medical care cost differen-
tial falls to about $90 to $120 per annum after the ﬁrst
year of therapy. If osteoporosis-related medical care costs
are not excluded, the cost differential is about $390 dur-
ing the ﬁrst year of therapy and $80 to $110 per annum
after the ﬁrst year of therapy. These excess costs primarily
are the result of excess rates of resource utilization for
uterine- and breast-related diagnostic and treatment
procedures.
Conclusion: Medical management costs for HT may be
substantial during the ﬁrst year of therapy, and some med-
ical management costs may persist over several years.
These short-term management costs, combined with
recent data about the long-term safety of HT as a preven-
tive therapy, reinforce the importance of considering ther-
apeutic alternatives to HT.
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Introduction
Estrogen plus progestogen hormone therapy (HT) is
used for the symptomatic treatment of menopause
and often has been used for the prevention of post-
menopausal osteoporosis. Rates of use have varied
substantially over time as perceptions have changed
about the relative beneﬁts and risks of HT. After the
discovery in the 1980s that the addition of a pro-
gestogen to estrogen therapy (ET) decreased the risk
of endometrial cancer, HT use steadily increased. By
1995, more than half of all postmenopausal women
in the United States had used either ET or HT at
least once [1–3].
However, recent data from the HT portion of the
Women’s Health Initiative (WHI) randomized trial
question the clinical value of HT as a long-term pre-
ventive therapy [4]. Speciﬁcally, although use of HT
over a 5-year period was associated with a reduc-
tion in the risk of osteoporotic fractures and color-
ectal cancer, HT use also was associated with an
increase in the risk of coronary heart disease (CHD)
events, stroke, breast cancer, and deep vein throm-
bosis/pulmonary embolism (DVT/PE). For other-
wise healthy women, the overall risks of HT were
judged to outweigh the beneﬁts of HT as a long-
term preventive therapy [5]. The implications of the
WHI ﬁndings for HT as a short-term treatment for
menopausal symptoms are less clear.
Although studies such as WHI have shed light on
the incidence of serious adverse effects of HT, little
is known about the levels of medical care resources
associated with the management of these events, or
any costs associated with the management of more
common minor adverse events of HT (e.g., abnor-
mal uterine bleeding, breast discomfort). More gen-
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erally, little is known about overall medical care
resource utilization and costs among HT users rel-
ative to nonusers after initiation of HT.
This study helps ﬁll these gaps by providing a
comparative analysis of medical care costs among
postmenopausal women in Saskatchewan, Canada
over an 8-year period from 1990 to 1997. We esti-
mate the net costs of HT use in a retrospective pop-
ulation-based study of HT users and nonusers. For
simplicity, we focus on women who were potential
candidates for combined estrogen–progestogen
treatment (i.e., postmenopausal women with an
intact uterus). The impact of the duration of HT use
also is assessed.
Background
Medical Management of  HT
As with virtually all prescription drugs, there are
adverse events associated with HT use. Rare but
serious adverse events include DVT/PE, CHD
events and stroke. Less serious but more common
adverse events (or “side effects”) include irregular
or abnormal vaginal or uterine bleeding, breast
pain, and increased breast nodularity. Serious but
relatively rare adverse events may have a signiﬁcant
impact  on  the  costs  associated  with  therapy  from
a population perspective if the cost per serious
adverse event is substantial. Minor adverse events
also can have a signiﬁcant impact on the cost of
therapy from a population perspective if these
events are common and the cost per event is not
small.
Several studies also have shown signiﬁcant
increased need for gynecologic procedures for eval-
uation among HT users compared to nonusers. In
retrospective case–control studies, Ettinger and col-
leagues found that the incidence of abnormal vagi-
nal bleeding requiring gynecologic procedures for
evaluation, such as endometrial biopsy, were higher
among HT users compared to nonusers, both for
women using cyclic progestogen-estrogen replace-
ment therapy [6] and continuous combined estro-
gen–progestogen therapy [7]. In another study, a
signiﬁcant percentage of physicians (16%) in Wash-
ington, Alaska, Montana, and Idaho reported
routinely using endometrial biopsies to monitor
patients receiving HT [8]. In a companion study to
the present study, Thorp et al. [9] found new HT
users were more likely to receive an endometrial
biopsy or a dilation and curettage procedure over
the ﬁrst 1 to 3 years of therapy. Results from these
retrospective and observational studies were con-
ﬁrmed in the WHI trial [10]. Among women not
scheduled for routine endometrial biopsy as part of
the study protocol, 33% of those assigned to HT
had an endometrial biopsy, compared to 6% in the
placebo group (P < 0.001). Of these, 38% (13%
overall) had more than one biopsy in the HT group,
compared to 16% (1% overall) in the placebo
group.
The absolute increase in breast cancer risk found
in WHI is small and similar to that found in obser-
vational studies of HT users [11–13]. Nonetheless,
the potential for increased breast cancer risk cou-
pled with increased breast symptoms may prompt
additional evaluation and lead to increased use of
mammograms among HT users. In addition, studies
have shown HT to reduce both the speciﬁcity and
sensitivity of mammograms [14,15]. This greater
uncertainty may lead to a greater number of sup-
plemental diagnostic tests and lower screening
effectiveness. For example, Thorp et al. [9] found
new HT users were more likely to receive a breast
biopsy during the ﬁrst 2 years of therapy. These
ﬁndings have been conﬁrmed by the WHI trial
[16]—women assigned to the HT group were more
likely to have abnormal mammography ﬁndings
resulting in additional evaluation than women
assigned to placebo during every year of therapy
(P < 0.001).
In addition to costs associated with diagnostic
procedures, minor adverse events also may contrib-
ute to costs if women experiencing these problems
return to their physician to obtain a new HT pre-
scription with a different active ingredient, strength,
administration form or regimen. Recent studies
have found that almost one-third of HT users
switched regimens, dosages or administration type
during an initial episode of use [2,17,18]. These
additional visits and prescriptions add to the costs
of managing HT.
The medical costs associated with managing HT
use must be considered against medical costs
averted due to the clinical beneﬁts of HT. These
beneﬁts historically have been presumed to include,
among others, a reduced incidence of osteoporotic
fractures and a reduced risk for CHD events. How-
ever, the recent WHI trial results conﬁrm earlier
ﬁndings of an increase CHD risk, at least early in
the course of HT [19–22]. If HT increases the risk
of CHD events during the ﬁrst year, short-term cost
could increase among HT users as a population,
even if such cases are relatively rare.
Some of the medical management costs may be
offset by the cost of events avoided as a conse-
quence of HT. For example, estimated total annual
medical care treatment costs among women 45 and
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older in the United States were almost $13 billion
for osteoporosis [23]. If HT is effective in prevent-
ing osteoporotic fractures, some of the substantial
costs of treating these fractures may be averted
among the population of HT users.
Design
Materials and Methods
Saskatchewan Health (SH) funds universal coverage
of a wide range of health services to its population
of about one million people. Information on health
service use is kept centrally in several linkable com-
puterized data ﬁles [24]. The Saskatchewan admin-
istrative databases include a health insurance
registration ﬁle, a cancer registry, and ﬁles with out-
patient prescription drugs, hospital services and
physician services data. We drew data from each of
these ﬁles for a set of women meeting our inclusion
criteria.
Inclusion  criteria.  We included postmenopausal
women with an intact uterus who were taking HT
primarily for its long-term prevention beneﬁts and
an equal number of postmenopausal women with
an intact uterus who had no medical contraindica-
tions to HT but did not use HT during the study
period. The study population was restricted to
women aged 55 years and over to exclude women
who took HT primarily for the alleviation of symp-
toms during perimenopause. We included women
who were 55 by January 1, 1990, as well as women
turning 55 between January 1, 1990 and December
31, 1994. However, we only included the woman’s
HT experience after her 55th birthday.
We also excluded women who had hospitaliza-
tions for a hysterectomy, thrombophlebitis, or a
thromboembolic disorder between 1970 and 1990
and women recorded in the cancer registry with a
diagnosis of breast cancer or uterine cancer between
1967 and 1990. These conditions often were con-
sidered contraindications to HT use. In addition,
because of incomplete data, we excluded women
residing in long-term care facilities, women whose
prescriptions were paid by a government agency
other than SH, and women with less than 4 years of
coverage under SH (1 year before taking HT and
3 years after initiation of HT).
Deﬁnition  of  HT  user. We identiﬁed an eligible
woman as an HT user if she had at least one pre-
scription ﬁlled from January 1, 1990 through
December 31, 1994 for: 1) a progestogen (medrox-
yprogesterone acetate, micronized progesterone,
norethindrone, or other progestogen-only oral
contraceptive) plus at least one estrogen (chlo-
rotrianisene, estradiol, conjugated estrogen, diethyl-
stilbestrol, estropipate, ethinyl estrodial) within
90 days of the progestogen prescription; 2) a com-
bination estrogen–progestogen transdermal treat-
ment (Estracomb); or 3) an oral contraceptive.
Women whose only estrogen prescription was for a
vaginal estrogen cream or whose only progestogen
prescription was for an injectable progestogen did
not qualify as HT users.
A total of 77,278 women met our inclusion cri-
teria. Of these women, 5726 women, or 7.4%, met
our deﬁnition of HT users. Because the oldest HT
user was 85 years of age by January 1, 1990, we
used this as an age cut-off for deﬁning the popula-
tion of potential users in Saskatchewan.
Deﬁnition of non-HT users. An equal number of
women who “never” used HT between January
1989 and December 1997 were matched to the
users based on age, marital status, and residence in
a large city, small city or rural area. The comparison
group women had to match exactly with HT users
on marital status (married or not married) and res-
idence, but could be 1 year older or younger than
the HT user. In addition, comparison group women
had to meet the same criteria on contraindications,
residence in long-term care facilities, and SH cover-
age as did HT users. The matching HT user’s index
prescription date was used as the date for ensuring
adequate follow-up among the never users.
For the analyses below, we summarized the data
for each woman into person-year summary records
for the calendar years from 1990 to 1997. We
included only women who were aged 55 years or
more during the analysis year and who remained
alive and covered by SH for the entire year. Thus,
the sample size varies by year, increasing from 1990
to 1994 as new women aged into the study and
declining slightly in the latter 3 years from loss to
follow-up. Because we wanted at least 3 years of
follow-up data, no new 55-year olds were added to
the study population from 1995 to 1997.
Measurement of  HT  use. We broke out HT users
by duration of HT use in the prior 2 years: 1)
women who had less than a full year of HT use in
the current year and no use in the preceding year
were designated as users with less than 1 year of
continuous HT use; 2) women who had used HT
for the full 12 months of the current year but only
part of the preceding year were designated to have
had 1 to 2 years of continuous HT use; 3) women
who had a full 12 months of HT use in the current
year and in the prior year were designated to have
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had more than 2 years of continuous HT use; and
4) women who had discontinuous use in the pre-
ceding 2 years or had used HT only during other
years of the study period were designated as “other
users.”
Measures of resource use. Costs were estimated by
payments made by SH to providers of care. Never-
theless, whereas the prescription and physician serv-
ice records in the SH database contain the payment
amounts, the hospital records had only a resource
intensity weight (RIW). The cost of a given hospi-
talization from 1992 to 1997 was computed by
multiplying the RIW by the estimated cost per
weighted case. The estimated cost per weighted case
was calculated by SH based on the available acute
care funding, minus funding related to emergency
room services and outpatient clinics, for a given
year divided by the total number of weighted cases
for that year. In 1996/97, the estimated cost per
weighted case was approximately $2,000. For hos-
pitalizations before 1992, a weighted average per
diem rate of $341 (in 1996/97 Canadian dollars)
was multiplied by the length of stay in days to esti-
mate short-term hospital costs. Current year physi-
cian service and prescription medication payments
were multiplied by the health-care component of
the Canadian Consumer Price Index to obtain con-
stant 1997 dollars.
Total costs were computed by summing aggre-
gated costs for physician services, prescription med-
ications and hospital care. Although these services
are the largest components of health-care costs, they
are missing some important resources. For instance,
the data ﬁle does not include radiology services con-
ducted at independent radiology centers. Because
HT use causes increased risk of breast pain and
nodularity that could prompt additional mammo-
gram use, our estimates of medical management
costs for HT could be underestimated and should be
considered conservative.
Finally, where Canadian dollars were converted
to US equivalent dollars, we multiplied the expend-
iture ﬁgures by the the Organization for Economic
Cooperation and Development’s (OECD) 1996
purchasing power parity for Canada divided by that
of the United States––a ratio of $1 Canadian to
$0.77 US [25].
Analytic Methods
We conducted a multivariate analysis of total
annual medical expenditures 1) excluding expendi-
tures for HT and lipid-lowering medications; and 2)
excluding expenditures for HT, lipid-lowering med-
ications, and osteoporosis treatment. Our goal for
the multivariate analysis was twofold: 1) to control
for any differences in the population that may affect
total medical care resource use other than the use of
HT; and 2) to identify expenditures for medical
management of HT net of any savings for HT from
treatment costs averted.
HT users may be either healthier or less healthy
on average than women not taking HT. To control
for potential selection bias, we included several
prior year health status variables in the multivariate
equations. These are total medical care resources
consumed in the prior year and indicators for
whether the woman had medical care contacts for
osteoporosis, CHD and menopausal disorders in
the prior year.
For robust variance estimates, we used a ﬁxed-
effect model and the general estimating equation
(GEE) method which accounts for both heteroske-
dasticity of the variances (i.e., unequal variances)
and the intercluster correlation of repeated meas-
ures on the same subject. Further, because the dis-
tribution of total medical care costs was skewed to
the right, we ran the regressions on the natural log-
arithm of total medical costs. The logarithmic spec-
iﬁcation gives less weight to very large costs. We
also dropped four high-cost outliers; three never
users with total costs of $123,143, $98,303, and
$83,318, respectively, and one current nonuser with
total costs of $99,971 were dropped. Women with
conditions requiring such high medical costs in a
single year would not be candidates for preventive
HT and therefore their exclusion is not believed to
bias our results.
Predicted medical management costs. Cost differ-
entials between HT users and nonusers could
result from differences in drug costs, any costs of
medical management of HT (dose titration, moni-
toring and treating side effects), and treatment
costs averted due to the clinical beneﬁts of HT.
The drug costs of HT were easily identiﬁed and
subtracted out from the total cost for HT users
before estimating the cost model. At the time of
the study, HT was often used as a lipid-lowering
drug among postmenopausal women, so the costs
of all lipid-lowering medications also were identi-
ﬁed and subtracted from total expenditures for
both HT users and never users. An alternative cost
metric further subtracted out costs associated with
osteoporosis treatment. However, the cost of treat-
ment for osteoporosis was not as easily identiﬁable
in the database as were drug costs; records with
diagnostic codes for osteoporosis may not include
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all related costs. Therefore, we computed these
costs from the estimated coefﬁcients for binary
(dummy) variables for any current-year medical
care for osteoporosis. Because we expected the
costs to vary by duration of HT use, we also
included interaction terms for osteoporosis treat-
ment and four HT user categories.
We estimated total costs for each HT user group
and for never users ﬁrst assuming the average prev-
alence of osteoporosis among the study population.
The differences in total costs between the user
groups and never users were then computed from
these totals. These differences are the apparent med-
ical management costs of HT net of any current-
year cost impact of HT on osteoporosis treatment
costs. We then recomputed medical management
costs ﬁrst for women without osteoporosis care in
the current year by setting the indicators for oste-
oporosis to zero. Using these estimates, we similarly
found the differences in total costs between the user
groups and never users. Predicted logarithms of
total and medical management costs were converted
to dollars by using HT-user-group-speciﬁc error
retransformation factors, computed as the average
exponential of the residuals.
As noted by Manning [26], retransforming the
expectation of a logged variable back into natural
units is complicated by heteroskedasticity. For this
reason, we used the HT-user-group-speciﬁc smear-
ing factors to account for the heteroskedasticity in
our sample. Another method, suggested by Mul-
lahy [27], involves estimating the relationship
using an exponential conditional mean (ECM)
regression model. To investigate the sensitivity of
our results to our choice of smearing factors, we
estimated our equations using ECM methods. All
results were qualitatively similar to the logarithmic
cost results.
Results
Characteristics of  the Study Population
Selected statistics on the demographic and health
characteristics of the study women are provided in
Table 1. Prior year health characteristics were meas-
ured in the 12 months preceding a user’s ﬁrst pur-
chase of a progestogen or estrogen prescription
after her 55th birthday. For nonusers, the prescrip-
tion purchase date of their matching user was used.
The average age of the study population as of
January 1990 was 57.2 years; more than 71% were
married; and 42% lived in one of Saskatchewan’s
two largest cities (Regina and Saskatoon), 17.5%
lived in the province’s smaller cities, and the remain-
ing 40.5% lived in rural areas. Users were more
likely to have used health-care services than nonus-
ers: they had signiﬁcantly more physician visits in a
12-month period, were signiﬁcantly more likely to
be hospitalized in that time, and had signiﬁcantly
higher total annual medical costs. Based on hospital
and physician service records, users were more
likely than nonusers to have had osteoporosis but
were equally likely to have had CHD.
Multivariate Analysis of  Total Annual Medical Costs
Of the 82,020 person-years of data for women
aged 55 years and over from 1990 through 1997, a
total of 4772 records were dropped because of the
lack of prior year data, leaving 77,248 person-years
for the analysis of all women. The estimated GEE
coefﬁcients for the logarithm of total medical
resource use are shown in Table 2. They should be
read as the percentage change in total medical
resources given a change in the associated explana-
tory variable.
The estimated coefﬁcients of the variables for
current HT users are positive and statistically
Table 1 Demographic and health characteristics of  HT users and nonusers in Saskatchewan Canada, 1990 to 1994
Users Nonusers
Number 5762 5762
Matching characteristics
Mean age in years (standard deviation) 57.2 (6.0) 57.2 (6.0)
Percent married 71.4% 71.4%
Percent residing in large cities 42.0% 42.0%
Percent residing in small cities 17.5% 17.5%
Health-care resource use in prior year†
Percent hospitalized 5.4%* 3.7%
Mean number of  physician visits, prior year (SD) 14.1 (12.5)* 9.2 (11.0)
Total medical costs‡ in prior year (SD) $1157 ($1876)* $857 ($2319)
Percent with physician visit(s) in year before ﬁrst HT prescription at age 55+† for
Osteoporosis 7.3%* 3.0%
Coronary heart disease 21.1% 20.9%
*Signiﬁcantly different from the estimate for nonusers at the P < 0.001 level.
†For nonusers, the prescription purchase date of  their matching user was used to determine the “prior year.”
‡Total medical costs here include costs for only physician services, prescription medications and short-term hospital stays.
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signiﬁcant (P < 0.001), with current HT users hav-
ing the largest coefﬁcient. The coefﬁcients for cur-
rent HT users with 1 to 2 years and users with more
than 2 years of use are roughly equivalent in
magnitude.
The coefﬁcient for osteoporosis-related medical
care in the current year is positive and statistically
signiﬁcant (P < 0.05). The interaction terms
between this variable and the current use indicators
are all negative and statistically signiﬁcant
(P < 0.001), suggesting that HT users with current
year osteoporosis-related medical care use had
lower medical care costs for osteoporosis than never
users.
Several other covariates had statistically signiﬁ-
cant estimated coefﬁcients in the model. Women
with higher total medical care costs in the prior year
had signiﬁcantly higher medical resource use in the
current year (P < 0.001). Current year medical
expenditures were higher among women with prior
year expenditures for osteoporosis (P < 0.05) or
CHD (P < 0.001). The coefﬁcient for a diagnosis of
menopausal disorders in the prior year is also sta-
tistically signiﬁcant (P < 0.001) but is relatively
small in magnitude. This may be a result of the lack
of speciﬁcity in this variable; because the SH physi-
cian services ﬁle only had three-digit ICD-9 (Inter-
national Classiﬁcation of Diseases, ninth revision)
codes, we could not distinguish hypestrogenic (e.g.,
hot ﬂashes) conditions requiring little medical inter-
vention and monitoring from hyperestrogenic (e.g.,
vaginal bleeding) conditions potentially requiring
signiﬁcant intervention and monitoring. The coefﬁ-
cient for the current year CHD medical care use var-
iable is positive and statistically signiﬁcant
(P < 0.001), and the interaction terms with the HT
user variables are negative and statistically signiﬁ-
cant (P < 0.001).
Total medical care expenditures also increased
with age (P < 0.001), and married women had
lower medical care costs compared to unmarried
women (P < 0.001). The coefﬁcient for residence in
a large city is positive and statistically signiﬁcant
(P < 0.001), but the coefﬁcient for residence in a
small city is not statistically signiﬁcant.
The coefﬁcients of the year dummies are positive
for 1990 to 1992 and negative for 1993 to 1996
(reference year 1997). As noted, due to availability
of cost information in the administrative data, the
methods used to estimate inpatient costs for 1990 to
Table 2 General estimating equation coefﬁcients (standard errors) for total annual medical care costs excluding costs for HT and
lipid-lowering medications
Coefﬁcients Standard errors
Intercept 2.94* (0.151)
Current HT user with <1 year continuous use (Never user omitted) 1.56* (0.039)
Current HT user with 1–2 year continuous use 1.20* (0.046)
Current HT user with >2 year continuous use 1.17* (0.033)
Other HT user (e.g., with discontinuous use) 0.98* (0.028)
Age 0.03* (0.002)
Resides in large city (rural omitted) 0.15* (0.028)
Resides in small city 0.02 (0.036)
Married -0.15* (0.029)
Medical care for CHD in prior year 0.32* (0.017)
Medical care for CHD this year 1.37* (0.024)
Current HT user with <1 year use -1.01* (0.062)
Current HT user with 1–2 year use -0.80* (0.081)
Current HT user with >2 year use -0.86* (0.045)
Other HT user -0.61* (0.035)
Medical care for osteoporosis in prior year 0.11† (0.037)
Medical care for osteoporosis this year 0.85* (0.066)
Current HT user with <1 year use -0.50* (0.106)
Current HT user with 1–2 year use -0.51† (0.163)
Current HT user with >2 year use -0.59* (0.105)
Other HT user -0.31* (0.084)
Medical care for menopausal disorders in prior year 0.12* (0.017)
Total medical costs in prior year (measured as percentage of  average) 0.07* (0.003)
1990 (1997 omitted) 0.20* (0.026)
1991 0.18* (0.024)
1992 0.07* (0.022)
1993 -0.09* (0.021)
1994 -0.19* (0.020)
1995 -0.17* (0.019)
1996 -0.04† (0.018)
Number of  person-years 77,248
*P < 0.01.
†P < 0.05.
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1992 differed from the methods used for 1993 to
1997. It is likely that the year dummy coefﬁcients in
part reﬂect this difference in costing methods over
time.
Predicted Medical Management Costs
Predicted total medical care costs for HT users, by
duration of therapy, and never users for the two
measures of cost are shown in Fig. 1. Total medical
care costs were higher for HT users than for never
users, regardless of whether we included or
excluded costs related to osteoporosis. In addition,
total medical care costs were signiﬁcantly higher for
current users with less than 1 year of use compared
to women with more than 1 year of continuous HT
use. Using the average prevalence of osteoporosis-
related care in the current year, we estimated med-
ical care costs to total $1237 (in 1997 Canadian
dollars) for women with new episodes of HT of
under 1-year duration. Subtracting the estimated
medical care costs for women who never used HT
during the study period yields an estimate of medi-
cal care costs attributable to HT use. As reported in
Table 3, the resulting attributable cost estimate is
about $390 during the ﬁrst year of HT use. This
estimate reﬂects higher costs among HT users due
to costs of medical management of HT adverse
events net of any cost savings due to HT use. Of
course, to estimate the total attributable costs of
HT, annual costs of $100 to $200 (or $77 to $154
in US-equivalent dollars) for the HT medications
must be restored to the estimated cost differentials.
However, the goal of the analysis is to estimate
costs associated with HT adverse events (HT med-
ical management costs). For this purpose, the cost
of drug therapy and any cost savings resulting from
the clinical beneﬁts of HT should be excluded. As
shown in Table 3, the attributable cost estimate
increases to about $400 if the cost of osteoporosis
care is excluded from both the HT-user and never-
user groups. In other words, the difference between
groups  in  osteoporosis  treatment  costs  during
the ﬁrst year of therapy is on average about $10.
Excluding this difference produces a more speciﬁc
estimate of HT medical management costs poten-
tially attributable to adverse events during the ini-
tial 12 months of treatment.
After the ﬁrst year of HT, apparent medical man-
agement costs for HT declined substantially, but dif-
ferences remained statistically signiﬁcant. Excluding
the costs of osteoporosis care from all groups, these
costs  were  estimated  to  be  in  the  range  of  $89
to  $126 annually. If osteoporosis costs are not
excluded, the estimated attributable costs of HT
after the ﬁrst year of therapy are about $77 to $112
annually.
Discussion
We investigated the level of medical care resources
used by postmenopausal women with an intact
uterus and no prior contraindications to combined
estrogen–progestogen replacement treatment in Sas-
katchewan, Canada from 1990 through 1997. Dif-
ferent patterns of medical care resource use were
found between HT users and nonusers and between
HT users with less than 1 year of use and those with
more than 1 year of continuous use. Because of the
considerable costs for managing HT in the ﬁrst year
of use, annual medical care resource use was highest
among women with new episodes of HT.
Excluding HT and lipid drug acquisition costs
and excluding costs associated with treatment of
osteoporosis, women in their ﬁrst year of postmen-
opausal HT use had total medical care costs about
Table 3 Predicted annual medical care costs by duration of  current HT use, 1997 Canadian dollars
Difference in costs between users and never users
Total costs less HT 
and lipid drug costs
Total costs less HT, lipid drug,  
and osteoporosis-related costs
Current HT users with <1 year of  use $389 $398
Current HT users with 1–2 years of  use $77 $89
Current HT users with >2 years of  use $112 $126
Figure 1 Estimated annual medical expenditures for current HT
users and never users by duration of  HT use (in 1997 Canadian
dollars).
$826$848
$1224$1237
$915$925 $952$960
$0
$250
$500
$750
$1000
$1250
$1500
Cost (less HT and lipid drugs) Cost (less HT, lipid drug & osteo-
porosis-related costs)
Never Used Current < 1 Year Current 1-2 Years Current > 2 Years 
Costs of Postmenopausal Hormone Therapy 551
$400 greater than postmenopausal women who had
not used HT, or about $308 in US-equivalent 1997
dollars. This total medical care cost differential falls
to about $89 to $126 per annum after the ﬁrst year
of therapy ($69–97 in US-equivalent dollars). If
potential osteoporosis-related cost offsets are not
excluded, the costs differential is about $390, or
$300 in US-equivalent dollars, during the ﬁrst year
of therapy and $80 to $110, or $62 to $85 in US-
equivalent dollars, per annum after the ﬁrst year.
That is, ﬁrst-year costs associated with managing
adverse events were partially offset by osteoporosis-
related costs that were $10 lower on average among
HT users relative to nonusers.
The apparent decline in the cost of managing
adverse events of HT with duration of therapy
could reﬂect a tendency for some adverse events,
such as abnormal bleeding, to occur less frequently
after the ﬁrst year of therapy. However, as noted,
Chlebowski et al. [16] found higher rates of abnor-
mal mammography results in the HT group com-
pared to the placebo group in each year of the WHI
study. Another possibility is that the reduction in
costs associated with duration of HT results in part
from differential rates of discontinuation of therapy
among women. If those experiencing adverse effects
of HT are more likely than others to discontinue
therapy, women who remain on therapy will tend to
be those with lower rates of adverse effects, and cor-
respondingly lower costs.
Limitations
A signiﬁcant limitation of this study is that women
receiving HT may differ from non-HT users along a
variety of characteristics that affect medical care
costs. This limitation is common to any retrospec-
tive case–control analysis. We have used a variety of
statistical adjustments for differences in observed
characteristics across HT users and nonusers in an
attempt to isolate the impact of HT on medical
costs. In particular, we have controlled for both gen-
eral patterns of medical care utilization before the
initiation of HT as well as speciﬁc pre-existing
comorbid conditions. A beneﬁt of the “cradle to
grave” health services coverage in the SH data, com-
pared to a US administrative database, is that there
is little attrition from the sample over time. As a
result, we were able to exclude all women who had
a hysterectomy or treatment for breast cancer over
a 20-year period before the study index date. How-
ever, as with any analysis of administrative health
data, some potentially relevant clinical characteris-
tics of the women included in the analysis cannot be
measured. Thus, our estimates of medical manage-
ment costs may overstate these costs if women
receiving HT also are more likely to use other serv-
ices for reasons not accounted for in the analysis.
Dummy variables for current-year treatment for
osteoporosis and CHD are used in the regression
model, but these variables potentially are endog-
enous. Thus, their estimated coefﬁcients could be
biased. Attributable cost estimates excluding oste-
oporosis costs are most likely to be affected by this
limitation, but the overall attributable cost esti-
mates may be affected as well. An alternative
approach would have been to construct an addi-
tional measure of “modiﬁed total” costs which
excluded osteoporosis-related cost for both HT
users and non-HT user controls as an alternative
dependent variable in the regression model. How-
ever, as noted, some osteoporosis-related costs are
not identiﬁable in the database through diagnosis or
treatment codes. Thus, a modiﬁed cost measure
excluding identiﬁable osteoporosis-related costs
would not provide a complete exclusion of
osteoporosis-related costs.
Another potential limitation of the analysis is the
focus on differences in modiﬁed total health-care
costs between HT users and matched nonusers. This
method is based on the assumption that any differ-
ence in modiﬁed total costs, after controlling for
other factors, is potentially attributable to HT. A
more restrictive alternative is to only compare costs
for speciﬁc procedures deemed likely to be related
to evaluation or treatment for adverse events of HT.
In addition, estimates of the attributable cost of HT
during the ﬁrst and subsequent years of therapy are
obtained indirectly from synthetic cohorts based on
coefﬁcients of the categorical variables relating to
patterns of HT use in the regression model for cal-
endar year modiﬁed total cost data. This method
follows that often used in prospective cohort stud-
ies, but an alternative would have been to identify
“new” episodes of HT use based on the date of an
initial HT prescription, and construct parallel epi-
sodes for each of the non-HT user controls based on
a matching pseudo-index date.
A related study [28; Ohsfeldt RL, Chawla A,
White LA, unpublished] provides a case–control
analysis using US private insurance claims data for
new episodes of HT use. The analysis focused on
costs for a speciﬁc set of uterine- and breast-related
evaluation and treatment procedures potentially
related to HT use over a 2-year period after an
index date for HT initiation for 902 new HT users
and 2135 nonusers age 50 to 64. An exponential
conditional mean regression model was used to esti-
mate medical care expenditures for these proce-
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dures over 2 years, controlling for observable
factors such as baseline comorbidity factors and
prior period medical care expenditures. The results
indicated that costs for potentially HT-related pro-
cedures were $362 higher (in 1997 US$) for HT
users compared to nonusers over the ﬁrst 2 years of
therapy. This estimate is remarkably similar to the
medical management cost estimates for the SH data
when expressed in US$ (i.e., $308 + $69 = $377).
While the similarities in these estimates (despite
the differences in methods) are reassuring, given the
limitations of both studies, additional research is
needed to conﬁrm or contradict the implications of
our analysis. The usual solution to the patient treat-
ment selection issue is to conduct a trial where
patients are randomized to treatment or placebo
groups. However, it would be difﬁcult to design a
randomized clinical trial to estimate medical man-
agement costs for HT in usual clinical practice.
Nonetheless, at a minimum it would be useful to
replicate this analysis using a large retrospective
database that permits the extraction of potentially
relevant clinical factors via access to patient medical
records.
Concerns about long-term safety of HT are less
relevant when considering HT as a short-term ther-
apy for the relief of menopausal symptoms, such as
severe hot ﬂushes. Even in this context, the costs of
managing adverse effects of therapy may be a rele-
vant factor to balance against the well-established
beneﬁts of HT for menopausal symptom relief,
especially if these costs during the ﬁrst year of ther-
apy are as great (or even greater) than HT drug
costs. However, an additional limitation of our
analysis is that it predates the advent of “low-dose”
HT. To the extent low-dose HT generally is associ-
ated with lower adverse event rates than standard-
dose HT, the costs of managing those adverse events
probably would be lower as well. More data about
the effectiveness and costs of low dose HT, as well
as nonhormonal alternatives to HT, are needed to
assess the beneﬁts and costs of alternative treat-
ments for menopausal symptoms.
Conclusion
Common minor adverse events that many women
experience when taking HT may generate signiﬁ-
cant costs during the ﬁrst year of therapy. These
medical management costs appear to diminish
among HT users over time but remain present for
several years. Given concerns about the long-term
safety of HT, current US Preventive Service Task
Force [29] guidelines encourage clinicians to con-
sider alternatives to HT for osteoporosis therapy,
despite the beneﬁts of HT for the prevention of oste-
oporosis. The apparent medical management cost
for HT may provide yet another reason to consider
alternative treatments for osteoporosis.
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